六个欧洲卫生技术评估机构在瘤药物有效性评估中的证据要求存在差异 - - 能否改善对齐?
相关实验视频
Updated: Jul 15, 2025

09:39
Assessing Specificity of Anticancer Drugs In Vitro
Published on: March 23, 2016
9.5K
Sharon Wolters1,2, Lisa A de Jong2, Christel Jansen3,4
1Asc Academics B.V, Groningen, The Netherlands.
Expert review of pharmacoeconomics & outcomes research
|September 25, 2023
概括
欧洲卫生技术评估 (HTA) 机构对瘤药物的证据要求有所不同,延迟了患者的获取. 通过协作和联合评估来加强协调,可以加快HTA决策并改善获得公平性.
科学领域:
- 卫生技术评估 卫生技术评估
- 瘤学 药物评估 药物评估
- 相对有效性研究研究比较
背景情况:
- 对于相对有效性评估的证据要求在欧洲卫生技术评估 (HTA) 机构之间有所不同.
- 这些变化影响HTA决策时间表和患者获得瘤药物的机会.
- 协调要求可以简化流程并提高公平性.
研究的目的:
- 分析欧洲HTA机构对瘤药物评估的证据要求的差异.
- 识别具有证据可接受性的显著差异的特定子域.
- 为加强HTA机构之间的协调提供建议.
主要方法:
- 在六个欧洲国家 (意大利,荷兰,波兰,葡萄牙,英格兰/威尔士,瑞典) 进行了利益相关者采访.
- 采访的重点是瘤药物评估中的各种子领域的证据要求.
- 分析涉及比较证据的可接受性和确定HTA机构之间的协调差距.
主要成果:
- 在外推的可接受性,类效应,代用终点 (例如,无进展生存),生活质量数据,单臂试验,交叉设计,试验持续时间和效果大小临床相关性方面观察到显著差异.
- 在HTA机构如何评估瘤药物的特定类型证据方面存在差异.
结论:
- 加强对证据要求的调整可以减少决策时间,并改善患者公平获取.
- 建议包括联合早期对话,加强跨国合作,联合相对有效性评估和使用访问协议.
相关概念视频
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Cancer Survival Analysis
380
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
380
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
145
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
145
Hazard Ratio
152
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
152

